CLBS201 in Patients with Chronic Kidney Disease (CKD) and Type 2 Diabetes Mellitus (T2DM)

Completed · Phase 1

Conditions studied: Chronic Kidney Diseases

In brief

CLBS201 will evaluate the safety, tolerability, and therapeutic effect in subjects with CKD and T2DM.

Key facts

Study ID

NCT04990427

Run by

Lisata Therapeutics, Inc.

People needed

6

Starts

2022-01-10

Expected to finish

2023-01-26

Last updated by the study team

2024-10-09

Who can join

Age: 18 and older, up to 75. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Adults aged 18 to 75 years, inclusive
• Documented diagnosis of type 2 diabetes
• eGFR of 30 to <45 mL/min/1.73m at the screening visit.
• UACR 300 mg/g to ≤ 5000 mg/g

You may not qualify if…

• Hemoglobin < 10 g/dL
• Hemoglobin A1c ≥8% at the time of screening
• Acute kidney injury within 6 months prior to screening

Where it is running

• Clinical Advancement Center, PLLC — San Antonio, Texas, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.